[{"id":"83d11ff4-3b7d-4444-9461-32ff2facba5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04103879","created_at":"2021-01-18T20:04:18.750Z","updated_at":"2024-07-02T16:35:18.963Z","phase":"Phase 2","brief_title":"US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia","source_id_and_acronym":"NCT04103879","lead_sponsor":"ExCellThera inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Zemcelpro (dorocubicel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/13/2020","start_date":" 11/13/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-02-19"},{"id":"d88c1ac7-6c49-4687-9631-89d59339a7df","acronym":"","url":"https://clinicaltrials.gov/study/NCT04990323","created_at":"2021-08-04T13:53:03.286Z","updated_at":"2024-07-02T16:35:18.901Z","phase":"Phase 1/2","brief_title":"US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies","source_id_and_acronym":"NCT04990323","lead_sponsor":"ExCellThera inc.","biomarkers":" HLA-DRB1 • CD34","pipe":"","alterations":" ","tags":["HLA-DRB1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan • Zemcelpro (dorocubicel) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-02-19"},{"id":"9ea4e22c-7e50-4995-ab97-e08e5092ac72","acronym":"","url":"https://clinicaltrials.gov/study/NCT03913026","created_at":"2021-01-18T19:15:26.504Z","updated_at":"2024-07-02T16:35:19.117Z","phase":"Phase 2","brief_title":"UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia","source_id_and_acronym":"NCT03913026","lead_sponsor":"Ciusss de L'Est de l'Île de Montréal","biomarkers":" TP53 • FLT3 • JAK2 • HLA-DRB1 • CD34","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RAS mutation • JAK2 mutation","tags":["TP53 • FLT3 • JAK2 • HLA-DRB1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RAS mutation • JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Zemcelpro (dorocubicel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2024-02-16"},{"id":"c2516a83-e25b-4521-afde-eaaf91d0d42c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03441958","created_at":"2021-01-18T16:58:32.149Z","updated_at":"2024-07-02T16:35:20.229Z","phase":"Phase 1/2","brief_title":"ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma","source_id_and_acronym":"NCT03441958","lead_sponsor":"Ciusss de L'Est de l'Île de Montréal","biomarkers":" CD34","pipe":" | ","alterations":" Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr t(4;14) • Chr t(14;16) • Chr t(14;20) • C1As"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • Zemcelpro (dorocubicel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/07/2018","start_date":" 03/07/2018","primary_txt":" Primary completion: 10/28/2023","primary_completion_date":" 10/28/2023","study_txt":" Completion: 10/17/2025","study_completion_date":" 10/17/2025","last_update_posted":"2024-02-08"},{"id":"caa50d59-c203-4e7f-93d3-79c9f5cf2ede","acronym":"","url":"https://clinicaltrials.gov/study/NCT02668315","created_at":"2021-01-18T13:00:28.871Z","updated_at":"2024-07-02T16:36:57.371Z","phase":"Phase 1/2","brief_title":"Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant","source_id_and_acronym":"NCT02668315","lead_sponsor":"Maisonneuve-Rosemont Hospital","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zemcelpro (dorocubicel)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 12/16/2015","start_date":" 12/16/2015","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 08/01/2018","study_completion_date":" 08/01/2018","last_update_posted":"2019-08-05"}]